Pivotal phase III trial investigating galactomannan-C (DAVANAT) in combination with standard chemotherapy in patients with metastatic colorectal cancer.
Phase of Trial: Phase III
Latest Information Update: 15 May 2012
At a glance
- Drugs Galactomannan C (Primary)
- Indications Colorectal cancer
- Focus Registrational; Therapeutic Use
- Sponsors Galectin Therapeutics
- 15 May 2012 This rial does not appear to have begun in 2011 as planned.
- 11 Jan 2011 Agreement for the design of this pivotal trial has been reached between the US FDA and Pro-Pharmaceuticals.
- 11 Jan 2011 Planned initiation date changed to 1 Jan 2011, based on information in a media release from Pro-Pharmaceuticals.